Equity Analysts at RBC Capital Maintained their Buy rating for Karyopharm Therapeutics (KPTI). The Target Given is $17; Trigran Investments Trimmed By $71.28 Million Its Integrated Device Technology (IDTI) Position

Integrated Device Technology, Inc. (NASDAQ:IDTI) Logo

Trigran Investments Inc decreased Integrated Device Technology (IDTI) stake by 87.61% reported in 2018Q3 SEC filing. Trigran Investments Inc sold 1.52 million shares as Integrated Device Technology (IDTI)’s stock rose 13.74%. The Trigran Investments Inc holds 214,558 shares with $10.09 million value, down from 1.73M last quarter. Integrated Device Technology now has $6.26 billion valuation. The stock decreased 0.10% or $0.05 during the last trading session, reaching $48.38. About 962,724 shares traded. Integrated Device Technology, Inc. (NASDAQ:IDTI) has risen 60.60% since February 27, 2018 and is uptrending. It has outperformed by 60.60% the S&P500. Some Historical IDTI News: 01/05/2018 – Integrated Device Volume Jumps More Than Six Times Average; 21/04/2018 – DJ Integrated Device Technology Inc, Inst Holders, 1Q 2018 (IDTI); 27/03/2018 – S&PGR Affrms IDT ‘BB-‘ Rtng; Outlook Rvsd To Pos From Stble; 23/03/2018 – Integrated Device Closes Below 50-Day Moving Average; 27/03/2018 – S&P Affirms ‘BB-‘ Corporate Credit Rating on IDT; 06/03/2018 IDT To Participate In Upcoming Investor Conferences; 09/04/2018 – IDT to Showcase Video Transcoding Innovations at NAB 2018; 09/03/2018 – HMD Global Unveils the Nokia 8 Sirocco Premium Smartphone Featuring IDT’s Leading-edge Wireless Charging Technology; 08/03/2018 – IDT to Showcase its Latest Optical Communication Solutions at OFC 2018; 04/04/2018 – Xiaomi Selects IDT® Wireless Charging Chipset for MI MIX 2S Smartphone and Wireless Charging Pad

Stock analysts at RBC Capital have $17 TP on Karyopharm Therapeutics (NASDAQ:KPTI). RBC Capital’s TP suggests a potential upside of 269.57% from the company’s previous close. The rating was revealed to clients and investors in analysts note on Wednesday, 27 February.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $279.26 million. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin??s lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

Analysts await Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report earnings on March, 21. They expect $-0.82 EPS, down 2.50% or $0.02 from last year’s $-0.8 per share. After $-0.79 actual EPS reported by Karyopharm Therapeutics Inc. for the previous quarter, Wall Street now forecasts 3.80% negative EPS growth.

Among 3 analysts covering Karyopharm Therapeutics (NASDAQ:KPTI), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Karyopharm Therapeutics had 4 analyst reports since November 9, 2018 according to SRatingsIntel. The firm has “Neutral” rating given on Thursday, January 3 by Bank of America. The firm has “Buy” rating given on Friday, February 22 by H.C. Wainwright. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has “Outperform” rating given on Friday, November 9 by Wedbush.

The stock decreased 5.74% or $0.28 during the last trading session, reaching $4.6. About 3.41M shares traded or 192.02% up from the average. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has declined 4.99% since February 27, 2018 and is downtrending. It has underperformed by 4.99% the S&P500.

Since August 29, 2018, it had 0 insider buys, and 20 selling transactions for $6.17 million activity. $126,304 worth of stock was sold by Shacham Sharon on Thursday, October 18. Shares for $145,593 were sold by Kauffman Michael. Chione Ltd sold $3.47M worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Wednesday, September 5. Mirza Mansoor Raza had sold 2,500 shares worth $50,000. The insider Primiano Christopher Brett sold 10,000 shares worth $189,046.

Investors sentiment decreased to 1.02 in Q3 2018. Its down 1.46, from 2.48 in 2018Q2. It is negative, as 7 investors sold Karyopharm Therapeutics Inc. shares while 34 reduced holdings. 18 funds opened positions while 24 raised stakes. 40.88 million shares or 2.58% less from 41.97 million shares in 2018Q2 were reported. Strs Ohio, a Ohio-based fund reported 25,900 shares. Swiss Savings Bank invested in 0% or 85,150 shares. Great West Life Assurance Com Can owns 5,686 shares. Amundi Pioneer Asset Mngmt holds 4,600 shares or 0% of its portfolio. Royal Fincl Bank Of Canada owns 1,595 shares. Kazazian Asset Management Ltd Liability Com accumulated 17,540 shares or 0.28% of the stock. Tcw Grp Inc Inc invested in 25,779 shares or 0% of the stock. Quantbot Techs L P holds 0.01% or 4,232 shares in its portfolio. Prudential Fin, a New Jersey-based fund reported 22,020 shares. Schwab Charles Inv Inc owns 271,988 shares. 49,400 were accumulated by State Of Wisconsin Board. Virtu Fin Ltd Liability Corporation has invested 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Geode Capital Ltd Liability holds 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 531,569 shares. Bluemountain Mngmt Lc has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Moreover, Frontier Com Ltd has 0.02% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI).

More notable recent Karyopharm Therapeutics Inc. (NASDAQ:KPTI) news were published by: which released: “Analysts Slash KaryoPharm (NASDAQ:KPTI) Price Targets By Over 50% After Adcom Setback – Benzinga” on February 27, 2019, also Seekingalpha.com with their article: “FDA advisory committee delays vote on Karyopharm’s selinexor – Seeking Alpha” published on February 26, 2019, Streetinsider.com published: “Karyopharm Therapeutics (KPTI) Confirms Trading Halted Ahead of FDA Advisory Committee Meeting to Discuss Selinexor – StreetInsider.com” on February 26, 2019. More interesting news about Karyopharm Therapeutics Inc. (NASDAQ:KPTI) were released by: Seekingalpha.com and their article: “Karyopharm socked by FDA briefing docs – Seeking Alpha” published on February 22, 2019 as well as Seekingalpha.com‘s news article titled: “Karyopharm shares halted ahead of Ad Com vote on selinexor – Seeking Alpha” with publication date: February 26, 2019.

Among 5 analysts covering Integrated Device Tech (NASDAQ:IDTI), 0 have Buy rating, 0 Sell and 5 Hold. Therefore 0 are positive. Integrated Device Tech had 5 analyst reports since September 4, 2018 according to SRatingsIntel. The stock of Integrated Device Technology, Inc. (NASDAQ:IDTI) has “Neutral” rating given on Tuesday, September 11 by Susquehanna. The company was downgraded on Tuesday, September 4 by Needham. Cowen & Co downgraded Integrated Device Technology, Inc. (NASDAQ:IDTI) rating on Tuesday, September 11. Cowen & Co has “Market Perform” rating and $49 target. KeyBanc Capital Markets downgraded the stock to “Sector Weight” rating in Tuesday, October 16 report. On Tuesday, September 11 the stock rating was downgraded by PiperJaffray to “Neutral”.

Since September 4, 2018, it had 0 insider buys, and 4 sales for $2.67 million activity. Shepard David sold $127,950 worth of stock. WATERS GREGORY L also sold $852,600 worth of Integrated Device Technology, Inc. (NASDAQ:IDTI) shares. Another trade for 33,300 shares valued at $1.57M was made by Chittipeddi Sailesh on Friday, September 14.

Trigran Investments Inc increased Sierra Wireless Inc (NASDAQ:SWIR) stake by 142,362 shares to 690,916 valued at $13.89M in 2018Q3. It also upped Quantenna Communications Inc stake by 281,969 shares and now owns 1.02 million shares. Brightcove Inc (NASDAQ:BCOV) was raised too.

More notable recent Integrated Device Technology, Inc. (NASDAQ:IDTI) news were published by: Nasdaq.com which released: “Notable ETF Outflow Detected – IWM, FIVE, ETSY, IDTI – Nasdaq” on February 27, 2019, also Nasdaq.com with their article: “Integrated Device (IDTI) Q3 Earnings & Revenues Top Estimates – Nasdaq” published on January 29, 2019, Nasdaq.com published: “Notable ETF Outflow Detected – IWO, FIVE, ETSY, IDTI – Nasdaq” on January 31, 2019. More interesting news about Integrated Device Technology, Inc. (NASDAQ:IDTI) were released by: Nasdaq.com and their article: “After-Hours Earnings Report for January 28, 2019 : CE, RGA, ELS, WHR, BRO, GGG, IDTI, WWD, CR, CHFC, JJSF, SSB – Nasdaq” published on January 28, 2019 as well as Nasdaq.com‘s news article titled: “Pre-Market Most Active for Feb 7, 2019 : TWTR, NOK, SLDB, FCAU, SQQQ, USAT, IDTI, QQQ, AMD, STI, TPR, ACB – Nasdaq” with publication date: February 07, 2019.

Investors sentiment is 0.85 in 2018 Q3. Its the same as in 2018Q2. It is without change, as 45 investors sold IDTI shares while 104 reduced holdings. only 74 funds opened positions while 52 raised stakes. 112.64 million shares or 7.09% less from 121.24 million shares in 2018Q2 were reported. The Illinois-based Trigran Invests Inc has invested 2.09% in Integrated Device Technology, Inc. (NASDAQ:IDTI). New York-based State Teachers Retirement Sys has invested 0.02% in Integrated Device Technology, Inc. (NASDAQ:IDTI). Bluecrest Capital Ltd stated it has 0.13% of its portfolio in Integrated Device Technology, Inc. (NASDAQ:IDTI). Engineers Gate Manager Lp holds 0.16% or 45,249 shares in its portfolio. Goldman Sachs Incorporated holds 830,336 shares or 0.01% of its portfolio. Smithfield Tru invested in 0% or 80 shares. Ing Groep Nv invested in 19,774 shares. Quantitative Mngmt Limited Liability holds 0.01% or 9,100 shares in its portfolio. Strs Ohio reported 21,900 shares. Employees Retirement Of Texas owns 0.05% invested in Integrated Device Technology, Inc. (NASDAQ:IDTI) for 74,000 shares. Manufacturers Life Company The accumulated 294,316 shares. Pennsylvania-based Pnc Fin Services Gp has invested 0% in Integrated Device Technology, Inc. (NASDAQ:IDTI). Schroder Inv Mgmt Grp, Maine-based fund reported 1.79M shares. Farallon Capital Mgmt Limited Liability Com accumulated 640,000 shares. 1.53 million were reported by Vaughan Nelson Mgmt Lp.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.